Ruchia Duggan is Group leader in the BRo5 modalities, including peptides and targeted protein degraders. DMPK lead on pipeline programs ranging from early discovery to development stage for small molecule and peptide therapeutics. Recognized SME in the beyond rule of 5 chemical space. She has a Ph.D. in Biochemistry with a passion for solving challenges in therapeutics and healthcare.